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ABSTRACT 
ELAINE BROOKS BOHÓRQUEZ: Role of the pfmdr1 gene in Plasmodium falciparum 
Resistance to Antimalarial Treatment 
(Under the direction of Dr. Steven R. Meshnick) 
  
 Plasmodium falciparum is an intracellular protozoan that causes the most severe 
form of malaria. A major hindrance to disease control efforts is the spread of drug 
resistant parasite populations, which has been linked to the Plasmodium falciparum 
multidrug resistance (pfmdr1) gene. Pfmdr1 encodes a transporter protein that pumps 
solutes, including antimalarials, into the parasite food vacuole. Elevated pfmdr1 gene 
copy number (CN) is thought to decrease parasite sensitivity to numerous antimalarial 
compounds, including quinine (QN) and mefloquine (MFQ). Therefore, our central 
hypothesis was that the efficacy of antimalarials is dependent upon the CN and 
expression of the pfmdr1 gene in P. falciparum. This hypothesis was addressed in the 
following objectives: (1) to determine pfmdr1 expression after MFQ treatment, (2) to 
determine the frequency of parasite subpopulations with elevated pfmdr1 CN in patients 
that fail antimalarial treatment, and (3) to determine the subcellular localization of QN. 
We found that MFQ exposure resulted in a clear upregulation of pfmdr1. Concomitant 
morphology analyses revealed that MFQ treatment delayed maturation through the 
normal intraerythrocytic cycle at the ring stage. Our data show that MFQ-induced 
increases in pfmdr1 expression are the direct result of the maturation delay and indicate 
that pfmdr1 is primarily expressed during the ring stage of development. Next, to 
iv 
 
understand the role of elevated pfmdr1 CN in clinical treatment outcome, we developed a 
limiting dilution assay to evaluate pfmdr1 CN in parasite subpopulations within an 
individual patient. We found that even small proportions of parasites with multiple 
pfmdr1 copies could affect the treatment outcome, which suggests that elevated CN has a 
stronger influence over treatment response than previously reported. Lastly, we explored 
the effect of multiple pfmdr1 copies on the subcellular localization of the fluorescent 
antimalarial compound, QN. We found that, regardless of pfmdr1 copy number, QN 
overlapped with hemozoin but did not colocalize with the acidotropic dye. These results 
suggest that QN localizes to a non-acidic compartment within the food vacuole and that 
pfmdr1 CN does not affect QN subcellular localization. Our results reveal novel data on 
pfmdr1 gene expression and the degree to which CN can affect clinical treatment 
outcome. 
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CHAPTER I 
Introduction 
 
GLOBAL BURDEN OF MALARIA 
The recorded history of malaria dates back to ancient times, including King 
Tutankhamun’s malaria infection at death (circa 1324 BC) and Hippocrates’ (460 BC – 
370 BC) description of the disease in his book Epidemics (1-3). The adaptability of 
malaria parasites is evidenced by the antiquity of the disease and its persistence today. In 
2009 alone, an estimated 225 million cases and 781,000 deaths worldwide were due to 
malaria (4). Human malaria is caused by obligate intracellular protozoa of the 
Plasmodium genus, of which there are 4 species: P. malariae, P. ovale, P. vivax, and P. 
falciparum. Although the latter 2 are the most common causes of malaria, particularly in 
South America and Southeast Asia, P. falciparum is responsible for the most severe and 
fatal form of the disease and accounts for 70% of malaria infections in Sub-Saharan 
Africa (Figure 1.1) (4, 5). 
 
PATHOGENESIS AND CLINICAL PRESENTATION OF MALARIA 
 Although several symptoms are typically associated with malaria infection, the 
clinical presentation can vary substantially depending on the level of parasitemia, species 
of Plasmodium, and the immune status of the infected individual. In high malaria 
transmission areas, such as sub-Saharan Africa, exposure to malaria-infected mosquito 
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bites occurs frequently allowing people to gradually develop immunity. Thus, many 
adults in these areas are infected but show few symptoms. Children under the age of five, 
however, are particularly at risk of clinical malaria, because they have not yet developed 
sufficient immunity (4). Alternatively, in low transmission areas, like Southeast Asia, 
exposure to infected bites is infrequent, resulting in a lack of malaria immunity among 
the population. In such settings, clinical malaria develops in most people that are 
infected. 
Clinical presentation of malaria can be divided into 2 categories: uncomplicated 
malaria and severe malaria. Uncomplicated malaria constitutes the vast majority of 
malaria cases worldwide. The initial symptoms are nonspecific and resemble those of 
many other febrile illnesses, including headache, chills, malaise, nausea, diarrhea, 
hepatosplenomegaly, and, most commonly, fever (6-8). The periodicity of fever that is 
sometimes observed coincides with the rupturing of infected red blood cells and release 
of parasites during the intraerythrocytic parasite life cycle (Figure 1.2). As infection 
progresses, rupturing erythrocytes can lead to anemia. Malaria is resolved by treatment 
with antimalarials or, eventually, by host immune responses. 
In some instances, infection may progress to severe malaria with systemic 
complications. Though high-grade parasitemia (>10% parasitized erythrocytes) likely 
triggers this progression to severe disease, the specific mechanism is unknown. Severe 
malaria is a complex multisystem disorder that is characterized by severe anemia, 
metabolic acidosis, and cerebral complications (9). These complications are 
predominantly caused by P. falciparum and can develop rapidly, progressing to death 
within a matter of hours or days (10). Malaria-naïve travelers returning from malaria 
  
 3 
endemic regions are most likely to suffer life-threatening complications from infection. In 
fact, the fatality rate in travelers with falciparum malaria may exceed 20% for severe 
malaria cases (11). In areas with high transmission rates, however, severe malaria is 
primarily a disease of young, non-immune children. A study of Gambian children with 
severe malaria showed that 14% of those that presented with cerebral malaria died. Of 
those that recovered, approximately 12% developed permanent neurological problems, 
including ataxia, tremors, blindness, and speech disorders (12). 
 
PLASMODIUM FALCIPARUM LIFE CYCLE 
 There are 2 hosts of the malaria parasite P. falciparum: Anopheles spp. mosquito 
and human. A small number of parasites that are circulating in the human bloodstream 
mature to form male and female gametocytes. These sexual stage parasites are ingested 
when a female anopheline mosquito takes a blood meal from an infected person. This 
begins the sexual development cycle and is responsible for malaria transmission (Figure 
1.2) (13). The lower body temperature of the mosquito allows the gametocytes to 
complete their maturation within the mosquito’s midgut (14). Here, fertilization results in 
a motile ookinete which moves through the cells of the stomach wall to form an oocyst. 
When this oocyst ruptures, the multiple sporozoites inside are released and migrate to the 
mosquito’s salivary glands (6). Plasmodium sporozoites are then transmitted to humans 
through the bite of this infected female Anopheles mosquito. These sporozoites migrate to 
the liver where they multiply inside hepatocytes to produce 105 to 106 of infective 
progeny, called merozoites, which are released into the bloodstream (15). 
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Merozoites invade circulating erythrocytes and initiate the asexual 
intraerythrocytic cycle, which is responsible for the symptoms and morbidity and 
mortality associated with malaria disease (13). Once inside the red blood cell, most 
parasites undergo profound transcriptional and morphological changes during the asexual 
48-hour life cycle (16, 17). The parasitophorous vacuole, which encases the parasite 
within the red blood cell, is formed following merozoite maturation to the ring stage. 
Rings then develop into metabolically-active trophozoites. During this stage, host 
hemoglobin is digested, and the toxic heme byproduct is detoxified by biocrystallization 
to form inert hemozoin crystals (18). The presence of hemozoin is characteristic of 
trophozoites as well as schizonts, which is the final developmental stage of the 
intraerythrocytic life cycle. During the schizont stage, DNA replication and mitosis occur 
to produce multinucleated schizonts that give rise to multiple merozoites. At the end of 
the 48-hour cycle, schizont-infected erythrocytes rupture and release the merozoites to 
infect other red blood cells, allowing the cycle to begin again and exponentially 
increasing parasite burden in the blood; up to 32 new merozoites may be released from 
each infected erythrocyte (17). 
 
ANTIMALARIAL DRUGS: MODES OF ACTION & MECHANISMS OF 
RESISTANCE 
Quinolines 
 Quinine 
 Although no one knows for certain who discovered it, the curative nature of the 
cinchona tree bark in South America was well-known in Europe in the latter 17th century 
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and was included in the third edition of the London Pharmacopoeia as Cortex peruanus in 
1677 (Peruvian fever bark) (19). The first scientific description of this plant came in 1742 
by Carl Linnaeus, though it would take another century before two French chemists 
would isolate from cinchona bark the antimalarial alkaloid quinine (Figure 1.3) (19). 
Since the mid-1800s, quinine has been used as a monotherapy or in combination with 
other drugs, like tetracycline, to treat both uncomplicated and severe falciparum malaria 
(20-23). 
 Despite its efficacy, treatment with the aryl aminoalcohol quinine has several 
disadvantages. First, quinine treatment generally requires a relatively long regimen (7 
days) for maximum cure, which affects adherence levels to quinine treatment. Second, it 
is poorly tolerated. Substantial side-effects, including vomiting and blurred vision, are 
induced by quinine and are mostly experienced during the second half of the treatment 
course by which time malaria-related symptoms have lessened (24). Such unpleasant 
side-effects also affect adherence to the treatment and could contribute to premature 
termination (25). And third, quinine has limited success for post-treatment prophylaxis 
and thus does not protect against recurrent infections in areas of high malaria 
transmission (24). 
Despite the longevity of its use as an antimalarial, the mechanism of action of 
quinine remains unknown. Various studies have indicated that transporter proteins 
located on the food vacuolar membrane modulate sensitivity to quinine, particularly the 
transporters encoded by the genes pfmdr1 and pfcrt (26-30). The P. falciparum multidrug 
resistance gene, pfmdr1, has been extensively studied for its involvement in parasite 
resistance to a variety of structurally distinct antimalarials (26-29, 31-42). In the case of 
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quinine, 3 single nucleotide polymorphisms (SNPs) in the pfmdr1 gene that result in 
amino acid substitutions (S1034C, N1042D, and D1246Y) have been linked to a quinine-
resistant phenotype: the introduction of these 3 SNPs into pfmdr1 of a quinine-sensitive 
P. falciparum isolate conferred quinine resistance. Removal of these same mutations 
from a quinine-resistant isolate confers sensitivity (29). However, no correlation between 
pfmdr1 SNPs and increases in the half maximal inhibitory concentration (IC50) of 
quinine has been reported in field studies (27, 28, 30). Increased pfmdr1 copy number has 
also been linked with decreased sensitivity to quinine (30, 32). Regarding the P. 
falciparum chloroquine resistance transporter gene, pfcrt, an amino acid substitution at 
position 76 modulates quinine sensitivity in laboratory experiments (43-45). However, 
this effect is largely dependent upon the background strain; the K76T substitution has 
been associated with reduced (44), elevated, or unchanged (45) quinine IC50s. 
Although decreasing sensitivity to quinine has been observed in Southeast Asia, 
quinine continues to be recommended for severe malaria (46). Yet, even for severe 
malaria, its use has dwindled in favor of newer drugs that have far fewer adverse side 
effects. Recent studies suggest that parenteral artesunate (discussed below) should 
replace quinine as the treatment of choice for adults and children alike (23, 47, 48). 
 
 Chloroquine 
 Malaria parasites have developed some degree of resistance to nearly all 
antimalarial therapies in use. After World War II, there was a period of significant 
reduction in disease burden following the introduction and very successful use of 
chloroquine as an antimalarial. Chloroquine (CQ) is a synthetic 4-aminoquinoline 
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compound (Figure 1.3) characterized by its rapid efficacy, availability, low toxicity, and 
affordability (49). A diprotic weak base, chloroquine can be found in its un-, mono-, and 
di-protonated forms. Uncharged chloroquine is the only form that freely diffuses into the 
parasite’s acidic food vacuole. Once inside, chloroquine becomes positively charged and 
accumulates within this organelle. Chloroquine accumulation has been found to be higher 
in chloroquine-sensitive parasites than in chloroquine-resistant strains (50, 51). In the 
metabolically-active intracellular trophozoite stage, the food vacuole is the site of 
hemoglobin digestion, which generates free heme (ferriprotoporphyrin IX) (52). The 
insoluble heme is toxic to the malaria parasite and thus must be detoxified. Malaria 
parasites have evolved a mechanism to detoxify heme and precipitate it in the form of the 
inert crystal, hemozoin (53). This detoxification step is inhibited by chloroquine, which 
binds to a dimeric form of oxidized heme called hematin. Thus, chloroquine interferes 
with hemozoin formation, and the chloroquine-heme complex is highly toxic to the 
parasite (54, 55). 
For several decades, chloroquine was the antimalarial drug of choice: highly 
effective, inexpensive, and well-tolerated; it was ideal for malaria endemic areas where 
resources are often limited. However, chloroquine resistance eventually developed in 
Southeast Asia and South America and quickly spread across the globe, rendering 
chloroquine virtually useless in many areas (56). Initial investigations into chloroquine 
resistance involved genetic crosses between chloroquine-sensitive and chloroquine-
resistant clones and mapped resistance to the pfcrt gene on chromosome 7 (57, 58). Like 
pfmdr1, a food vacuolar membrane transporter protein called the P. falciparum 
chloroquine resistance transporter, PfCRT (Figure 1.4a), is encoded by the pfcrt gene. 
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SNPs within this gene modulate sensitivity to chloroquine by reducing accumulation in 
the food vacuole (44, 59, 60). In particular, a mutation that is ubiquitous in chloroquine-
resistant clones encodes an amino acid change at position 76 (K76T), the removal of 
which results in full restoration of chloroquine sensitivity (45). These in vitro results are 
consistent with in vivo findings that report a strong association between the K76T 
substitution and chloroquine treatment failure (49, 61). Thus, the mutation that causes the 
K76T substitution is now used as a molecular marker for chloroquine resistance. 
 
 Mefloquine 
Because of the rapidity with which parasite resistance to antimalarial compounds 
develops, there is a constant need to develop alternative therapies with plasmocidal 
activity. In response to the chloroquine resistance encountered during the Vietnam War, 
the United States Army began to develop new antimalarial drugs to treat infections 
caused by chloroquine-resistant parasites (62). The synthetic arylaminoalcohol 
mefloquine (Figure 1.3) was promising as a prophylactic agent, due to its long 
elimination half-life (10-23 days) (62). Requiring only one dose per week, mefloquine 
was ideal for people traveling to malaria endemic areas for extended periods of time and 
is still used by the U.S. Army today. 
In the early 1970s, mefloquine entered initial testing for therapeutic efficacy. 
While mefloquine was found to be highly effective as an antimalarial therapy (>90% cure 
rate in initial trials with single-dose regimens), it should be noted that, even when initially 
introduced, mefloquine was not 100% effective (63, 64). Mefloquine monotherapy was 
employed in 1976 for chloroquine-resistant malaria in Southeast Asia (63), and, despite 
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careful regulation of mefloquine distribution and use, resistance arose within 6 years of 
use (61). The likely reason for this rapid development of resistance is the long half-life of 
mefloquine (65). Drugs with long elimination half-lives pose 2 therapeutic benefits for a 
patient: (1) they require fewer doses for efficacy, and (2) they can provide long-term 
protection against reinfection. The downside of persistent drug levels is that the residual 
drug can be a potent selective force for parasites to develop antimalarial drug resistance 
(66, 67). Thus, what is therapeutically advantageous for an individual is a disadvantage 
for the population. 
Like many other antimalarial compounds, mefloquine was employed in 
prophylaxis and treatment regimens without the elucidation of its mode of action, which 
remains unknown. Even before candidate drug resistance genes were identified, 
mefloquine and chloroquine resistance phenotypes were found to be reciprocally related; 
mefloquine resistance corresponded to increased chloroquine sensitivity and vice versa 
(68-70). The P. falciparum multidrug resistance gene, pfmdr1, was initially investigated 
in the context of chloroquine resistance. Although many subsequent studies demonstrated 
that pfmdr1 may be part of a multigenic response for chloroquine resistance (29, 40, 71-
73), there is substantial evidence supporting its involvement in the mefloquine resistance 
phenotype (26-29, 31-33, 37-39, 74-77). The protein encoded by pfmdr1 (Pgh1) has been 
implicated as a specific target of antimalarial drugs, such as mefloquine, a known 
modulator of Pgh1 (78). However, previously conducted studies demonstrate evidence to 
the contrary (76, 79). Thus, the definitive target of mefloquine is still unknown. Due to 
the rapid development of mefloquine resistance among P. falciparum parasite 
populations, mefloquine monotherapy was discontinued and new avenues were 
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investigated for antimalarial therapy (64). Endoperoxides, like artemisinin (discussed 
below), showed promising plasmocidal activity. Combination therapies revitalized 
mefloquine use through the addition of artemisinin or its derivatives. 
 
Artemisinin and its derivatives 
 Multidrug-resistant falciparum malaria is now a serious problem in Southeast 
Asia, where resistance to chloroquine, quinine, and mefloquine are frequently found (61). 
This resistance has been curbed to some degree through the use of artemisinin-based 
combination therapies (ACTs), which are recommended by the WHO as the first-line 
treatment of uncomplicated falciparum malaria in malaria endemic regions (4). 
Artemisinin (qinghaosu), originally isolated from the Artemisia annua plant in 1972, is a 
sesquiterpene lactone that contains an endoperoxide bridge (C-O-O-C) essential for 
antimalarial activity (Figure 1.3) (80). The manner in which this endoperoxide bridge 
elicits plasmocidal activity is unknown. Two prevailing theories exist: (1) artemisinin 
interacts with heme via alkylation, generating free radicals that result in cell death (81-
84); or (2) artemisinin inhibits falciparum sarcoplasmic/endoplasmic reticulum Ca2+-
ATPase (PfSERCA), which is a protein responsible for maintaining calcium ion 
concentrations (85-87). 
Whereas strong evidence of artemisinin and heme interactions was observed both 
in vitro and in an in vivo mouse model of malaria (81, 88, 89), a later study suggested that 
heme alkylation may not be responsible for artemisinin’s antimalarial activity (90). 
Subsequent studies demonstrated the involvement of PfSERCA proteins in artemisinin 
activity and also in parasite resistance to artemisinin and its derivatives (85-87, 91, 92). 
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The only SERCA-type Ca2+-ATPase in P. falciparum is PfATP6, which is completely 
inhibited by artemisinin treatment. This inhibition is highly specific and all other 
transporters remain unaffected (87). Further support lies in the antagonistic activity of 
artemisinin and thapsigargin, which inhibits mammalian SERCA. Indeed, the inhibitory 
profile of artemisinin was exactly superimposable over that of thapsigargin, indicating 
that both drugs have the same target (86). A single amino acid substitution (L263E) in 
PfATP6 has been shown to modulate parasite sensitivity to artemisinin (85). Although 
there are studies suggesting alternative mechanisms for the plasmocidal activity of 
artemisinin that do not involve PfATP6 (93-95), these experiments were primarily 
conducted in yeast models and should be explored in malaria parasites to evaluate these 
alternative targets in the context of malaria infection. With P. falciparum parasites in 
Southeast Asia developing resistance to artemisinin, understanding the mechanism of this 
resistance is of utmost importance as there are currently no suitably effective alternative 
drugs (87, 91, 96). 
 
PFMDR1 AND ITS ROLE IN P. FALCIPARUM ANTIMALARIAL RESISTANCE 
 Pfmdr1 stands for P. falciparum multidrug resistance gene and was identified by 
Cowman et al. (1991) while investigating potential genes involved in malaria chloroquine 
resistance. Pfmdr1 is the parasite homolog to a multidrug resistance gene found in 
mammalian tumor cells (97), making it a good candidate for the broad spectrum 
resistance to structurally distinct antimalarials (42). Located on chromosome 5, pfmdr1 
encodes a 12 transmembrane-domain protein called P-glycoprotein homolog 1 (Pgh1) 
(Figure 1.4b), due to its homology to the mammalian ATP-binding glycoprotein (P-
glycoprotein, P-gp). Mammalian P-gp is believed to function as an energy-dependent 
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pump. With an ATP-binding domain on the cytoplasmic side of the tumor plasma 
membrane, P-gp couples ATP hydrolysis with drug export from the cell thus lowering 
intracellular levels to sublethal concentrations (98). Unlike P-gp, which is located on the 
plasma membrane of the mammalian cell, P. falciparum Pgh1 was found, using 
immunoelectron microscopy, to localize to the acidic parasite food vacuole (42) and has 
been implicated in regulation of intracellular drug concentrations (76, 99). Since Pgh1 
resides in the food vacuole membrane, its expression is largely restricted to the asexual 
metabolically-active trophozoite stage of the erythrocytic cycle (42). Pgh1 is also thought 
to have a role in active transport of antimalarial drugs; however, based on recent work by 
Rohrbach et al. (2006), transport is suggested to pump drugs into the vacuole rather than 
out, since the ATP-binding domain faces the cytoplasmic side of the vacuolar membrane 
(76). Further evidence of transporter function was demonstrated by a heterologous 
complementation assay of ste6 (mating factor) in Saccharomyces cerevisiae, which 
showed that pfmdr1 encodes a functional ABC transporter (100). 
 Initially, pfmdr1 was investigated as a possible source for resistance to 
chloroquine because the chloroquine resistance phenotype resembled that of multidrug 
resistant mammalian tumor cells; both involved drug expulsion and could be reversed by 
calcium channel antagonists, like verapamil (101). Though Wellems et al. (1990) showed 
through genetic crosses of chloroquine-resistant and chloroquine-sensitive P. falciparum 
strains that resistance was not linked to the pfmdr1 locus (102), several subsequent 
studies linked chloroquine resistance to point mutations within the pfmdr1 coding region, 
perhaps as part of a multigenic resistance mechanism (41, 103-106).  
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Single Nucleotide Polymorphisms 
 Five polymorphic regions of pfmdr1, revealed by initial sequence analyses of 
chloroquine-resistant lines, result in amino acid substitutions at the following loci: N86Y, 
Y184F, S1034C, N1042D, and D1246Y (101). The N86Y substitution, found in an 
isolate from Thailand, is located just before the third hydrophobic transmembrane 
segment of Pgh1 (101); this is a comparable position to a change in mammalian 
multidrug resistance gene that alters substrate specificity of P-gp (107). While the N86Y 
mutation was shown to augment chloroquine resistance in in vitro studies, this occurred 
only when the resistant allele of pfcrt (K76T substitution) was present in the same 
genome (57, 72, 108, 109). This co-selection of the pfmdr1 N86Y and pfcrt K76T 
substitutions by chloroquine treatment suggests that either these two genes work together 
to determine chloroquine resistance or deleterious pfcrt mutations are compensated for by 
the pfmdr1 N86Y (110). Interestingly, N86Y was shown affect parasite response to other 
antimalarials as well: in vitro studies suggest that the mutant allele augments resistance to 
quinine but increases sensitivity to mefloquine, halofantrine, and artemisinin (35, 110). 
A role for the other 4 mutations (Figure 1.4b) has been more difficult to ascertain 
(56, 77). Position 1042 in pfmdr1 is homologous to a residue that modulates multidrug 
resistance on mammalian mdr3 and was shown to affect P. falciparum sensitivity to 
chloroquine, mefloquine, and artemisinin (34). Both N1042D and S1034C are located 
within the same transmembrane segment of Pgh1, likely on the hydrophilic side of an 
amphipathic helix (101). Introducing mutations at pfmdr1 positions 1034, 1042, and 1246 
in a chloroquine-sensitive falciparum strain had no effect on chloroquine response; yet, 
replacing substituted amino acids with wild-type residues at these positions in a 
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chloroquine-resistant strain reduced resistance by half (29). These results suggest that 
these mutations are insufficient to confer resistance in the sensitive strain but that they 
may provide a cumulative effect with mutations in other genes to confer higher levels of 
resistance in chloroquine-resistant parasites (29). Interestingly, position 184, while highly 
polymorphic, does not appear to play a significant role in resistance at all. For instance, 
although Y184F was found in CQ-resistant parasites along with the other 3 mutations, 
Y184F was also identified in chloroquine-sensitive parasites, suggesting that this 
polymorphic position is not involved in chloroquine resistance (101). Additionally, 
Y184F was not significantly associated with resistance to mefloquine or artemisinin (35). 
 
Pfmdr1 Gene Copy Number 
 There are many cases in biology, including mosquito genes involved in 
insecticide resistance and bacterial genes responsible for adaptations to the environment, 
where phenotypic effects are elicited by gene copy number changes (111-113). Multiple 
copies in both prokaryotes and eukaryotes generally arise from gene duplication followed 
by amplification. The initial duplication step is rate-limiting and can occur via one of two 
mechanisms: (1) homologous recombination involving large regions of homology that 
employs RecA protein in prokaryotes and RAD52 in eukaryotes, or (2) illegitimate 
recombination involving short regions of homology without employing either of these 
proteins. The abundance of monomeric A/T tracts found in the P. falciparum genome is 
consistent with the latter mechanism (114). Subsequent amplification events occur via 
homologous recombination utilizing the large regions of homology generated by the 
initial duplication. Notably, these duplications occur more frequently than point 
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mutations but also tend to revert to a single-copy state more frequently due to unequal 
recombination (114). 
In the case of P. falciparum, the most extensive copy number polymorphism, in 
terms of size and frequency, is located on chromosome 5 and encompasses the pfmdr1 
gene in all strains studied (75, 115). Because the P. falciparum genome is extremely A/T-
rich (80.6% in the genome of strain 3D7 and up to 90% within introns and intergenic 
regions (116)) and thus less stable than DNA with higher G/C content, gene duplication 
events are common. Monomeric A/T tracts found near pfmdr1 were significantly longer 
than the genome-wide average, identifying a probable hot spot for gene duplication (114). 
The pfmdr1 gene was found to be particularly prone to copy number increases, rendering 
the parasite resistant to mefloquine and quinine, both in vitro and in vivo (115). The 
similarity between drug-selected laboratory strains and evidence of amplification events 
found in clinical samples indicate that initial duplications likely occur during the mitotic 
blood stages of the parasite life cycle (69, 114).  
 Although the mechanism of pfmdr1-mediated multidrug resistance is still 
unknown, increases in pfmdr1 gene copy number is highly associated with mefloquine, 
quinine, and artemisinin-based combination therapy (ACT) failure in both in vitro and 
clinical studies (27, 31, 32, 39, 56, 76). A large-scale study in Thailand revealed that 
pfmdr1 copy number is highly associated with multidrug resistance; 64% of mefloquine-
resistant isolates demonstrated more than 1 copy of pfmdr1 (37). This was confirmed in 
vitro to show that increased resistance to a number of antimalarials, including 
mefloquine, quinine, and artemisinin, was the result of multiple pfmdr1 gene copies (26, 
56). These additional copies were found to arise from multiple independent events and 
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were shown to occur in tandem along the same chromosome, suggesting that pfmdr1 is 
under strong selective pressure (42, 117). However, while pfmdr1 copy number increases 
occur frequently, there is a fitness cost to parasites with multiple pfmdr1 copies in the 
absence of drug pressure; without the drug, these parasites eventually revert to the single-
copy state (118).  
While the relationship between pfmdr1 copy number and drug resistance has been 
well documented both in vitro and in clinical studies (27, 31, 32, 36, 39, 114, 118-120), 
the effect of this change on gene expression is unclear. In order to explain a previously 
observed increase in pfmdr1 transcript in drug resistant parasites, two possible 
mechanisms have been suggested (40, 121, 122): (1) a gene amplification model, and (2) 
a transcript induction model. The gene amplification model suggests simply that a 
parasite containing multiple copies of a gene leads to over-expression of the transcript 
and protein. This is the case for mammalian multidrug resistant (mdr) gene (123, 124). 
Likewise, drug-resistant P. falciparum strains selected in vitro for mefloquine resistance 
contain more than one copy of pfmdr1 and have higher transcript levels (40, 121, 122, 
125). Mefloquine-resistant field isolates also had higher pfmdr1 copy numbers and over-
expressed the transcript (56, 76). In contrast, the transcript induction model suggests that, 
upon drug exposure, gene expression increases above levels seen in the absence of drug. 
For example, the drug sensitive P. falciparum strain, 3D7, was treated with several 
antimalarials to study how addition of drug influences pfmdr1 transcript levels. Transcript 
levels increased 2.5-fold in parasites treated with chloroquine, mefloquine, and quinine, 
but not with the structurally-unrelated drug, pyrimethamine (126). Thus, adding drug 
increased the amount of pfmdr1 transcript present, and this result appeared to be a drug-
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specific effect. However, no such induction studies have been performed on laboratory 
strains already containing multiple copies of pfmdr1; such experiments are necessary to 
ascertain if drug-induced pfmdr1 transcript increases would be found in parasites already 
possessing more than one pfmdr1 copy. 
 
DISSERTATION OBJECTIVES AND RELEVANCE 
  The focus of this dissertation was to evaluate the role of pfmdr1 gene copy 
number on parasite response to antimalarial treatment. There were 3 main objectives that 
guided this body of work: (1) assess the effect of increased copy number on pfmdr1 gene 
expression and response to mefloquine treatment in vitro; (2) evaluate whether multiple 
pfmdr1 copies affects subcellular localization of the fluorescent antimalarial compound, 
quinine; and (3) determine the proportion of parasites with increased pfmdr1 copies 
within an infected individual and test whether that relates to treatment response. 
 First, the data outlined in chapter 2 address the question of mefloquine’s effect on 
pfmdr1 expression in parasites with multiple copies of the pfmdr1 gene. Understanding 
how copy number results in the MFQ resistant phenotype will provide insight into 
possible mechanisms of MFQ action and will be crucial for making future decisions on 
implementing antimalarial regimens that include MFQ. 
 Second, the ability of Pgh1, the ABC transporter encoded by pfmdr1, to transport 
compounds across the food vacuolar membrane likely has a role in parasite response to 
antimalarial treatment. Chapter 3 evaluates the consequence of additional pfmdr1 gene 
copies on subcellular localization of quinine, particularly if multiple copies results in 
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increased trafficking of quinine into the acidic food vacuole. This, coupled with parasite 
response to quinine, may indicate possible sites of action within the malaria parasite. 
 Finally, the clinical relevance of increased pfmdr1 copy number is addressed in 
chapter 4. The structure of the parasite population within an individual patient will 
provide great insight into the minimum percentage of parasites with increased pfmdr1 
copies that is necessary to result in clinical treatment failure. 
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Figure 1.1: Global distribution of endemic Plasmodium falciparum. Infection 
prevalence is indicated by variations in color intensity: light green represents areas with 
an infection prevalence of ≤10%; medium green depicts 11-50% prevalence; and dark 
green represents the highest prevalence, ≥50% (127). Figure taken from Snow et al., The 
global distribution of clinical episodes of Plasmodium falciparum malaria. Nature. 2005. 
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Figure 1.2: Plasmodium life cycle. Plasmodium parasites have a complex life cycle that 
spans 2 hosts and 3 stages: (1) sexual stage in the Anopheles mosquito host which is 
important for malaria transmission; (2) asymptomatic stage in the human liver wherein 
parasite burden amplifies; and (3) asexual blood stage in the human, responsible for 
malaria symptoms. The morphologies depicted here are for P. falciparum, except for the 
hypnozoite, which only occurs in P. ovale and P. vivax (6). Figure taken from Griffith et 
al., Treatment of malaria in the United States: a systematic review. JAMA. 2007. 
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Figure 1.3: Chemical structures of antimalarial compounds. (a) Quinine; (b) 
Chloroquine; (c) Mefloquine; (d) Artemisinin. Structurally-related quinolines are shown 
in (a), (b), and (c). Artemisinin (d) is structurally distinct and is derived from the 
wormwood herb, Artemisia annua. 
 
(a) Quinine     (b) Chloroquine 
 
     
 
 
 
 
 
(c) Mefloquine     (d) Artemisinin 
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Figure 1.4: Predicted topologies of P. falciparum Chloroquine Resistance 
Transporter (PfCRT) encoded by pfcrt and P-glycoprotein homolog 1 (Pgh1) 
encoded by pfmdr1. (a) PfCRT has 10 predicted transmembrane domains. The K76T 
mutation found in all chloroquine-resistant strains is indicated in red. (b) Pgh1 has 12 
transmembrane domains and 2 nucleotide-binding domains (NBD). Single nucleotide 
polymorphisms that encode amino acid changes associated with antimalarial resistance 
are indicated. Figure from Valderramos and Fidock. Transporters involved in resistance 
to antimalarial drugs. Trends Pharmacol Sci. 2006 (56). 
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CHAPTER II 
Mefloquine Exposure Induces Cell Cycle Delay and Reveals Stage-Specific Expression 
of the pfmdr1 gene 
 
INTRODUCTION 
With 225 million estimated clinical infections that result in 781,000 deaths 
annually, the protozoan Plasmodium falciparum causes the most severe form of malaria, 
(4). Efforts to control malaria have been hampered by the development of resistance to 
antimalarials such as chloroquine, sulfadoxine-pyrimethamine, and mefloquine (MFQ). 
Artemisinin-based combination therapies (ACT) are now the first-line treatment for 
falciparum malaria. Unfortunately, resistance to these new drugs is believed to be 
developing based on the observation of slower in vivo parasite clearance times (61, 91, 
128). The molecular basis for resistance is unclear; thus, a better understanding of the 
ACT resistance mechanism is needed. 
Early investigations into antimalarial resistance led to the identification of a 
malaria homolog to the mammalian multidrug resistance gene (42, 101, 103). The P. 
falciparum multidrug resistance gene (pfmdr1) encodes an ATP-binding cassette protein 
called P-glycoprotein homolog 1 (Pgh1), which is located on the parasite food vacuole 
membrane (42) and functions as a transporter (76). The transporter function of Pgh1 
couples ATP hydrolysis with solute import into the food vacuole (129). The pfmdr1 gene 
has been identified as a possible modulator of resistance to a number of antimalarials 
(97), and the Pgh1 protein has also been implicated as a specific target of antimalarial 
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drugs, such as MFQ (78). Substantial data support a relationship between the pfmdr1 
gene and MFQ resistance both in vitro and in vivo (27, 31, 33, 37-39, 41, 74, 75, 118). 
Specifically, an abundance of in vitro and clinical data link higher pfmdr1 gene copy 
number and expression with reduced parasite susceptibility to drugs such as quinine 
(QN), MFQ and, more recently, artemisinin (27, 31, 32, 39, 41, 114, 118, 120, 129-133). 
The control of pfmdr1 gene expression is only partially understood. MFQ-
resistant field isolates with higher pfmdr1 copy numbers over-express the transcript 
compared to isolates with a single copy of pfmdr1 (56, 76), indicating a direct correlation 
wherein more gene copies results in higher constitutive expression. Expression may also 
be inducible; a recent study demonstrated higher pfmdr1 transcript levels in a strain 
bearing a single pfmdr1 gene copy after treatment with CQ, MFQ, and QN (126). This 
suggests that exposure to quinoline drugs can induce pfmdr1 expression and thereby, 
possibly augment resistance to antimalarials such as artemisinin and its derivatives. This 
is of particular importance because artesunate-mefloquine is a common ACT. In this 
study, we sought to expand on these observations to better understand the mechanism of 
pfmdr1 induction and how this might affect parasite sensitivity to artemisinins. 
 
MATERIALS AND METHODS 
Parasite cultivation 
 We used P. falciparum cultures of three clonal parasite lines obtained from the 
Malaria Research and Reference Reagent Resource Center, MR41: (1) 3D7: one pfmdr1 
copy, sensitive to CQ and MFQ, (2) FCB: 2 copies, CQ-resistant and MFQ-sensitive, and 
(3) Dd2: 4 pfmdr1 copies, resistant to CQ and MFQ. Parasite cultures were maintained at 
                                                
1 MR4: Manassas, VA 
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37°C using the standard Trager-Jenson method for malaria parasite culture (134). Pooled 
human type O+ serum at 10% and red blood cells2 at 2% hematocrit were used for all 
cultures and experimental conditions. Cultures were synchronized with 5% sorbitol 
solution every 48 hours for three consecutive life cycles to obtain a uniform culture of 
parasites at a single stage (135). 
 
Gene expression analysis 
Sorbitol-synchronized ring stage parasites were exposed to 100 ng/mL MFQ for 
48 hours. Total RNA was isolated from cultures at 0, 6, 12, 24, and 48 hours after 
addition of drug using TriReagent3, according to the manufacturer’s instructions. Real-
time reverse transcriptase (RT)-PCR was employed to assess relative pfmdr1 (reference 
ID for pfmdr1 from the Plasmodium Genomics Database, PlasmoDB, is PFE1150w) 
mRNA levels between parasite lineages using the ΔΔCt analysis, as previously described 
(136). The Ct value represents the PCR cycle at which DNA amplification crosses the 
threshold value. The ΔCt for each sample is defined as Ctpfmdr1-CtPfLDH. Differences in 
pfmdr1 gene expression for untreated cultures were compared to expression from single-
copy 3D7 untreated cultures. Differences in pfmdr1 expression for mefloquine-treated 
cultures were compared to the corresponding untreated culture of the same strain. In 
experiments involving drug exposure, untreated cultures were used as the negative 
control, and atovaquone (ATQ)-treated (1µM) cultures were used to control for effects on 
gene expression due to the addition to the culture media of a drug with a known site of 
action distinct from the pfmdr1-encoded protein. Expression of the developmentally-
                                                
2 Research Blood Components, LLC: Boston, MA 
3 Molecular Research Center, Inc.: Cincinnati, OH 
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regulated trophozoite antigen R45-like (PlasmoDB: PFD1175w), tar45-like, gene, which 
is transcribed during the ring stage only, was assessed using a SYBR Green assay as 
previously described (137). Single-copy P. falciparum lactate dehydrogenase 
(PlasmoDB: PF13-0141) gene, pfldh, was used as the reference gene for analysis. 
The primers and fluorescent probes for pfmdr1 were designed using ABI’s Primer 
Express software and are as follows (5’ to 3’): (1) pfmdr1 forward primer: 
TGCCCACAGAATTGCATCTATAA, (2) pfmdr1 reverse primer: 
GACTGTACAAAGGTTCCATTTCGA, and (3) pfmdr1 probe: FAM-
ACGATCAGACAAAATT-MGB. The published primers and fluorescent probes for the 
pfldh and tar45-like genes  (137) were used and are as follows (5’ to 3’):  (1) pfldh 
forward primer: ACGATTTGGCTGGAGCAGAT, (2) pfldh reverse primer: 
TCTCTATTCCATTCTTTGTCACTCTTTC, (3) pfldh probe: FAM-
AGTAATAGTAACAGCTGGATTTACCAAGGCCCCA-TAMRA, (4) tar45-like 
forward primer: ACGAGCTGACCCACCAAA, and (5) tar45-like reverse primer: 
CATTTAAGTCTGTCTTCATTCTACTTCT. Real-time RT-PCR amplifications were 
performed in a 96-well plate in the ABI Prism 7700 sequence detection system in a total 
volume of 30µL: 100ng RNA plus PCR reaction mixture to reach a total volume of 30µL. 
Each real-time RT-PCR amplification was performed in duplicate using a previously 
reported method that combines cDNA synthesis and real-time PCR in one reaction: 30 
min. at 48°C for the RT reaction, then 10 min. at 94°C, followed by a total of 40 PCR 
cycles (15 sec. at 94°C and 1 min. at 60°C) (136). During the amplification, the 
fluorescence of FAM, TAMRA, and ROX (a passive reference dye) was measured by the 
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7700 sequence detector in each well of the 96-well plate. All experiments were conducted 
a minimum of 3 times for statistical analysis. 
 
Morphology analysis 
Thin blood smears were prepared and stained with Giemsa stain4 at 0, 6, 12, 24, 
and 48 hours after the addition of MFQ. Parasitemia and parasite morphology were 
assessed via light microscopy.  Parasitemia was calculated as the number of parasitized 
red blood cells per 1,000 total red blood cells. Morphology was examined and the number 
of parasites at each asexual blood stage was assessed for a minimum of 100 parasites. 
Parasite morphologies were classified as follows: (1) parasites with a single nucleus and 
characteristic ring appearance were classified as rings; (2) parasites containing a single 
nucleus and hemozoin were considered trophozoites; and (3) multinucleated parasites 
with ample hemozoin represented schizonts. 
 
IC50 Determinations 
 Parasite drug susceptibility was determined using a modification of a published 
SYBR Green I flow cytometry assay (138). Drug concentration required to inhibit 50% of 
parasite growth was calculated using the sigmoidal dose response nonlinear regression 
equation in GraphPad Prism software. 
 
Statistical Analysis 
 Each experiment was conducted a minimum of three times for statistical analysis. 
All statistical analyses were conducted on the raw data (ΔCt) for each condition using 
                                                
4 Sigma-Aldrich Co.: St. Louis, MO 
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JMP Software5. Tukey’s test was used to determine significant differences at P≤0.05 
between the parasite strains because significance is determined for all possible pairwise 
comparisons of the three strains. The student’s t test was used to determine significant 
differences at P≤0.05 between untreated and drug-treated expression levels. 
 
RESULTS 
Pfmdr1 expression was proportional to copy number 
Synchronized parasites from three clonal strains of P. falciparum with different 
pfmdr1 gene copy numbers were used. Total RNA was isolated at several time points 
during the 48-hour asexual blood stage life cycle. In untreated parasites, pfmdr1 gene 
expression was directly proportional to the number of pfmdr1 gene copies present in the 
parasite: Dd2 parasites (four pfmdr1 gene copies) had higher expression of pfmdr1 
transcript than 3D7 (one copy) or FCB parasites (two copies) (Figure 2.1). These 
differences are significant (P<0.05) for Dd2 parasites through the 24-hour time point. The 
results indicate that there is a direct relationship between pfmdr1 copy number and 
expression of the pfmdr1 transcript. 
 
Mefloquine exposure caused increased pfmdr1 gene expression 
 Our results show that, compared with pfmdr1 transcript levels in the respective 
untreated culture for each strain, the exposure to mefloquine (MFQ) in all three strains 
tended to upregulate the expression of pfmdr1, with the increase appearing to be an early 
response that occurred within the first 6 hours (Figure 2.2). Although we consistently saw 
higher pfmdr1 expression in MFQ-exposed parasites compared with untreated parasites 
                                                
5 SAS Institute, Inc.: Cary, NC 
  
 29 
of the same strain, these results were significant only after synchronized rings of 3D7 
with one copy of pfmdr1 (P<0.005) and Dd2 with four copies of pfmdr1 (P<0.05) were 
exposed to MFQ for 12 hours. Pfmdr1 upregulation was observed only after exposure to 
MFQ but not to atovaquone (ATQ), suggesting that increased pfmdr1 expression is a 
specific P. falciparum response to MFQ and not a generalized response to antiparasitic 
drug treatment (data not shown). Similar trends, though not significant, were seen when 
drugs were added to synchronized parasites at the trophozoite stage. 
 
Mefloquine induced P. falciparum cell cycle delay 
Parasite maturation through the asexual blood stages was evaluated by thin blood 
smears using light microscopy. We found that the addition of MFQ to synchronized ring-
stage parasites delayed parasite maturation at the ring stage (Figure 2.3). In all strains 
tested, delay in maturation began at 6 hours post-treatment and became more pronounced 
by the 12-hour time point. This phenotype occurred following exposure to MFQ only. 
The addition of ATQ did not result in the same delay in maturation. Figure 2.4 shows that 
when MFQ was added to synchronized trophozoites, maturation proceeded normally until 
the ring stage, at which point maturation again stalled. Thus, MFQ appears to have a 
selective effect on ring-stage parasites. 
 
MFQ treatment resulted in increased expression of ring stage genes 
To confirm the effects of MFQ on parasite development, we used real-time PCR 
to test the expression of the developmentally-regulated trophozoite antigen R45-like 
(tar45-like) gene (PlasmoDB: PFD1175w), which is transcribed during the ring stage 
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only (137). The fold difference in tar45-like gene expression relative to pfldh was higher 
12 hours after treatment with MFQ (Table 2.1), whereas tar45-like gene expression was 
not affected by ATQ. These data confirm that MFQ-treated parasites remained in the ring 
stage for a longer period of time than untreated parasites. 
 
Pfmdr1 was primarily expressed during the ring stage of the intraerythrocytic cycle  
Untreated cultures of each parasite strain were assessed for morphology and 
pfmdr1 gene expression as described above. A direct relationship was observed between 
the proportion of ring-stage parasites in the culture and the fold difference in pfmdr1 
transcript levels (Figure 2.5). These data suggest that ring stage parasites express higher 
levels of the pfmdr1 transcript than later stages and that the MFQ-induced increase in 
pfmdr1 expression could be due to the maturation delay. 
 
MFQ-induced maturation delay had no effect on artesunate IC50 
Because MFQ-treated parasites expressed more pfmdr1, we tested to see whether 
MFQ treatment might antagonize its common partner drug, artesunate. Parasites were 
exposed to MFQ for 12 hours to induce the maturation delay. The half maximal 
inhibitory concentration (IC50) of artesunate was assessed on MFQ-exposed parasites. A 
SYBR Green I flow cytometry assay was used to quantify parasite growth inhibition by 
artesunate, as previously reported (138). We found no difference in artesunate IC50 
values between untreated and MFQ-treated parasites (Table 2.2). 
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DISCUSSION 
The objective of this study was to determine how mefloquine (MFQ) treatment 
affects pfmdr1 gene expression in parasites with different pfmdr1 gene copy numbers. 
We found that the expression of pfmdr1 was upregulated following MFQ treatment, and 
parasites with four pfmdr1 copies expressed higher transcript levels than single-copy 
parasites. Interestingly, cultures of MFQ-sensitive FCB parasites (two pfmdr1 gene 
copies) did not exhibit a significant increase in pfmdr1 expression following MFQ 
treatment compared with single-copy 3D7 parasites at any of the time points assessed. 
One possible explanation is that there may be a threshold for the number of pfmdr1 gene 
copies required for a parasite to exhibit the MFQ-resistant phenotype. Because these 
parasite strains are not isogenic, it is also possible that other genes could exert an effect 
on the parasite response to MFQ. Studies in which the expression from the additional 
pfmdr1 gene copies is reduced or eliminated in Dd2 parasites would be useful in 
evaluating the specific role of pfmdr1 on MFQ resistance. 
Upregulation of pfmdr1 following MFQ treatment was consistently observed in 
all strains. However, the results were statistically significant only for 3D7 and Dd2 
parasites at the 12-hour time point. Although the reason for this is unclear, subsequent 
analysis of parasite morphology on the sampled cultures to correlate our pfmdr1 
expression data with parasite life cycle revealed an interesting phenotype. In agreement 
with a recent report that studied MFQ exposure on synchronized rings only (139), our 
results revealed that MFQ treatment of synchronized ring-stage parasites resulted in a 
delay in parasite maturation at the ring stage of development. When we analyzed the 
morphology of synchronized trophozoites, we observed that MFQ exposure at the 
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trophozoite stage also caused the parasites to stall but only after the parasites matured 
through the intraerythrocytic cycle to the ring stage. This indicates that MFQ only 
affected the parasites’ ability to proceed through the asexual intraerythrocytic cycle when 
ring stage parasites were exposed to the drug. 
Two theories can explain the increase in pfmdr1 expression in response to MFQ 
exposure: (1) direct induction of pfmdr1 gene expression by MFQ; or (2) an indirect 
upregulation due to the maturation delay. At each time point assessed, a direct 
relationship was observed between pfmdr1 expression levels and the proportion of ring-
stage parasites in the culture. In one interval, between 12 and 24 hours, the change in 
pfmdr1 expression was consistently greater than the change in the proportion of ring 
stage parasites. This could be due to the difficulty in distinguishing late rings and early 
trophozoites by light microscopy. 
To demonstrate that MFQ-treated parasites were stalled at the ring stage and were 
not dying parasites, we investigated the expression levels of the developmentally-
regulated trophozoite antigen R45-like (tar45-like) gene, which is normally expressed in 
the ring stage. Transcripts of tar45-like also increased, peaking at 12 hours after the 
addition of MFQ. This increase was not observed in untreated or atovaquone-treated 
cultures, which also did not exhibit maturation delay. Thus, the observed increases in 
pfmdr1 transcript levels in the persistent rings found in MFQ-treated cultures are likely 
due to an overall increase in the expression of ring-stage genes. Ring stage-dependent 
transcription of pfmdr1 would explain the apparent induction of expression after 
treatment with a drug that slows the cell cycle at the ring stage. 
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Cell cycle delay upon drug exposure is a common phenomenon, most often seen 
in cancer cells (140-143). Recently, such delays have been described in P. falciparum 
(137, 139, 144, 145). Drug-induced delay in parasite maturation through the 
intraerythrocytic cycle was seen after short-term MFQ exposure in MFQ-sensitive strains 
(139). Similarly, we showed that treatment of synchronized ring-stage parasites with 
MFQ induced a delay in parasite maturation in both the MFQ-sensitive (3D7, FCB) and 
MFQ-resistant (Dd2) P. falciparum strains tested. Our data revealed that this delay was 
only slightly altered in Dd2 parasites, which have four pfmdr1 copies. MFQ-induced 
maturation delay occurred as early as 6 hours post-treatment and was observed after 
MFQ treatment but not after ATQ treatment, which indicates that the delay is not a 
generalized response to the presence of any antimalarial compound. Because decreased 
sensitivity to other quinoline drugs has also been linked to elevated pfmdr1 copy number, 
studies to evaluate the effect of other quinoline compounds, like quinine, on parasite 
maturation would be useful to understand if this delay is due to a certain structural class 
of antimalarial drugs.  
There are two possible explanations for the observed effects of MFQ on parasite 
maturation: (1) the presence of MFQ exerts an effect on the parasites’ ability to progress 
through the asexual cell cycle, or (2) the maturation delay is an active response by the 
parasite to the presence of MFQ. If the maturation delay is caused by MFQ, then it would 
likely be a nonspecific response, perhaps due to a disruption in the availability of 
nutrients or energy for the parasite to be able to continue through its normal asexual 
cycle. The addition of chemical agents that inhibit protein synthesis, like cyclohexamide 
for example, could shed light on this as a possibility. However, if the maturation delay is 
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an active response by the parasite, one possible consequence of the disruption in parasite 
cell cycle is to allow time for parasites to survive peak serum drug concentrations by 
preventing the maturation to intraerythrocytic stages that express the drug target. Such is 
the case for certain chemoresistant or radioresistant phenotypes observed in cancer cells 
(146, 147). For example, 5-fluorouracil (5-FU) is a chemotherapeutic agent that 
specifically targets the S phase of the eukaryotic cell cycle. Cancer cells resistant to 5-FU 
are known to arrest at the G1 phase following 5-FU exposure, thus preventing the drug 
from engaging its S-phase target (146). These delays are directly linked to the treatment 
dose and duration, and the removal of the therapy restores normal cell cycle. In P. 
falciparum, MFQ-induced cell cycle delay is also dose-dependent, and removal of MFQ 
drug pressure restores cell cycle proliferation (139). This would explain the maturation 
delay if MFQ activity is in one of the later intraerythrocytic stages. 
A second, and perhaps more interesting, explanation for the maturation delay and 
expression increase could be that the delay is an initial response that allows time to 
increase expression of drug transporters to evade destruction. Delay at the ring stage 
results in an upregulation of ring stage genes including pfmdr1 that would result in 
greater transport capacity due to the presence of more transporter proteins. For P. 
falciparum parasites that possess multiple copies of pfmdr1, this delay-induced 
expression increase would result in many more transporter proteins than single-copy 
strains and may displace sufficient amounts of MFQ to allow the parasite to survive 
treatment. Our observations of MFQ-induced maturation delay and the ring stage-specific 
transcription of pfmdr1 support this hypothesis and could explain why multiple pfmdr1 
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copies are linked with a resistant phenotype even though all strains exhibit the maturation 
delay. 
Despite the rapid evolution of resistance to MFQ, its use has gained new life in 
combination with artemisinin derivatives. Some evidence suggests that the activity of 
artemisinin and its derivatives is stage-specific, with greater plasmocidal activity on late-
stage rings and trophozoites than on schizonts or early rings (148-151), whereas other 
evidence indicates activity on all blood stages (151-153). If the former is true, then MFQ 
should be synergistic with artesunate. On the other hand, elevated pfmdr1 copy numbers 
have been implicated as a cause of artesunate resistance as well. Thus, if MFQ leads to 
increased pfmdr1 expression, then it could be antagonistic with artesunate. We found no 
differences in the artesunate IC50 after MFQ exposure, which suggests that it is neither 
synergistic nor antagonistic. Thus, no evidence was found against combining artesunate 
and mefloquine in malaria treatment. 
An abundance of in vitro and clinical evidence links copy number increases in the 
P. falciparum multidrug resistance gene with resistance to several antimalarial 
compounds (27, 31, 32, 39, 114, 118, 120, 128, 133). Our results on the maturation delay 
and the stage-dependent transcription of pfmdr1 provide new insight into possible 
resistance mechanisms mediated by copy number changes. The slowing of the parasite 
intraerythrocytic cell cycle in response to MFQ appears to be a general survival response 
by all P. falciparum strains tested. This delay could function to alleviate time constraints 
by prolonging the ring stage, providing the opportunity for higher production of drug 
transporter proteins in parasites containing multiple pfmdr1 gene copies. Further studies 
are needed to fully understand the mechanism by which MFQ slows cell cycle 
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progression and if this does increase the relative amount of pfmdr1-encoded transporter 
expressed in each parasite. Particularly, investigation into whether or not MFQ has an 
effect on cell cycle regulators, such as P. falciparum homologs for cyclin-dependent 
kinases (155-161), would be worthwhile to determine if MFQ delays maturation by 
interfering with one or more cell cycle enzymes. 
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Figure 2.1: Fold differences in pfmdr1 gene expression over time in parasite strains 
with different pfmdr1 copy numbers. Transcript levels of pfmdr1 relative to the single-
copy P. falciparum lactate dehydrogenase gene were evaluated over time following 
synchronization using real-time RT-PCR. Fold differences in pfmdr1 expression are 
relative to 3D7 expression at each time point (not shown), which was set to 1 (black line). 
Parasite strains with more than one pfmdr1 copy had higher levels of transcript than 
single-copy 3D7 parasites. These results were significant for Dd2 through the 24-hour 
time point. Results are from 6 independent experiments. Statistics were done on the raw 
data (ΔCt) at each time point. *P<0.05, Tukey’s test. 
  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
0h 6h 12h 24h 
Fo
ld
 D
iff
er
en
ce
 in
 p
fm
dr
1 
ex
pr
es
si
on
 re
la
tiv
e 
to
 3
D
7 
Time (hours) 
FCB (two copies) 
Dd2 (four copies) 
* 
* 
* * 
* 
  
 38 
 
 
 
Figure 2.2: Fold change in pfmdr1 gene expression in parasites with different pfmdr1 copy 
numbers over time following mefloquine exposure. Fold changes in pfmdr1 expression are 
relative to the corresponding untreated culture for each strain at each time point (not shown), 
which were set to 1.0 (black line). Significant increases in pfmdr1 expression upon mefloquine 
exposure were observed at the 12-hour time point for 3D7 and Dd2 cultures. Results are from 6 
independent experiments. Statistics were done on the raw data (ΔCt) at each time point. *P<0.05 
and **P<0.005, Student’s t test. 
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Figure 2.3: Morphology stage development of untreated and drug-treated parasites. 
Blood stages of 3D7 (1 pfmdr1 copy), FCB (2 copies), and Dd2 (4 copies) parasites were 
monitored in untreated, atovaquone (ATQ)-treated, and mefloquine (MFQ)-treated parasites 
over time. Untreated and ATQ-treated cultures progressed through the normal asexual cell 
cycle. MFQ treatment caused a delay in parasite maturation, resulting in a persistence of ring-
stage parasites. All strains exhibited this delay. 
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Table 2.1: Fold differences in tar45-like gene expression after 12 hours of drug exposure in parasites 
with different pfmdr1 copy numbers 
 
Parasite Straina Atovaquone-treatedb Mefloquine-treatedb 
3D7 1.31 5.73 
FCB 1.02 6.14 
Dd2 1.47 6.48 
 
aPfmdr1 copy number of each parasite strain is as follows: 3D7 has one pfmdr1 gene copy, FCB 
has two copies, and Dd2 has four copies. 
bFold differences in tar45-like expression levels are relative to untreated levels for each strain at 
the 12 hour time point, which were set to 1.00. Results are from two samples for each condition. 
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Figure 2.4: Morphology stage development of untreated and MFQ-treated synchronized 
trophozoite parasites. Synchronized trophozoites of 3D7 (1 pfmdr1 copy), FCB (2 copies), and 
Dd2 (4 copies) parasites were monitored in untreated and mefloquine (MFQ)-treated parasites 
over time. Untreated cultures (top graph) progressed through the normal asexual cell cycle. MFQ 
treatment caused a delay in parasite maturation at the ring stage (bottom graph), resulting in a 
persistence of ring-stage parasites. All strains exhibited this delay. 
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Figure 2.5: Ring stage-specific expression of pfmdr1 in untreated parasite strains 
containing different pfmdr1 copy numbers. Untreated cultures of each parasite strain 
were assessed for morphology (lines) and pfmdr1 gene expression (bars) relative to P. 
falciparum lactate dehydrogenase. A direct relationship between the proportion of ring 
stage parasites in the culture and the relative expression of pfmdr1 was observed. 
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Table 2.2: Half maximal inhibitory concentration (IC50) of artesunate in parasite cultures before 
and after exposure to mefloquine (MFQ). 
Parasite Strain Untreated Mefloquine-treatedc 
3D7a 0.61 ± 0.04nM 0.62 ± 0.07nM 
Dd2b 0.39 ± 0.05nM 0.40 ± 0.02nM 
a3D7 parasites contain one pfmdr1 gene copy. 
bDd2 parasites contain four pfmdr1 gene copies. 
cMFQ-treated cultures were exposed for 12 hours to MFQ prior to IC50 analysis. 
 
  
  
  
 
 
 
CHAPTER III 
Novel Limiting Dilution Real-Time PCR Assay for the Detection of Subpopulations of 
Parasites within Individual Patients Infected with Plasmodium falciparum 
 
INTRODUCTION 
One of the major complications to malaria control efforts is the spread of drug 
resistant parasites. Drug-resistant Plasmodium falciparum is now a serious problem in 
Southeast Asia, where resistance to a number of antimalarials is common (61, 162). 
Western Cambodia has been an epicenter for the emergence of antimalarial resistance, 
where chloroquine resistance was first reported in the late 1950s (163). As chloroquine-
resistant parasites pervaded the malaria population, mefloquine (MFQ) was adopted in 
1976 as the first-line treatment for P. falciparum (64). Although its use was carefully 
regulated, significant resistance to MFQ monotherapy rapidly developed (27). As a result, 
combination therapies involving artemisinin derivatives, specifically artesunate-
mefloquine (AM), were introduced in 1995 (64). While these are more effective at 
parasite clearance than MFQ alone, clinical treatment failure, or recrudescence, to AM 
has emerged (31, 91, 130). The declining efficacy in recent years of AM therapy 
confirms the need to fully explore the parasite populations of this region in order to 
understand the resistance mechanisms and spread of drug-resistant parasites. 
As resistance to new antimalarial therapies arises, understanding how mutations 
evolve is needed. Resistance to MFQ in vitro is linked to both single nucleotide 
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polymorphisms (SNPs) and gene copy number in the P. falciparum multidrug resistance 
gene (27, 31, 32, 118, 120, 122, 130, 132, 133). Elevated pfmdr1 copy number has also 
been linked to increased resistance to both MFQ monotherapy and AM in vivo. 
Individual patients are frequently infected with multiple genetic variants of 
malaria parasites at once, often with a mixture of both drug-sensitive and drug-resistant 
variants. Theoretically, someone infected with predominantly drug-sensitive parasites 
might fail therapy because of a low level of drug-resistant parasites. The ability to detect 
minority variants with higher pfmdr1 copy numbers might be able to better predict in vivo 
antimalarial treatment failure. Pfmdr1 copy number has traditionally been measured 
using real time PCR and measures the average copy number of all parasites within the 
individual. In order to be able to study the proportion of parasites with elevated pfmdr1 
copy number within an individual patient, we developed a limiting dilution real-time 
PCR assay to assess pfmdr1 copy number of parasite subpopulations present in a mixed 
infection. The purpose of this study was to evaluate the distribution of subpopulations 
with different pfmdr1 copy numbers in patients before and after artesunate-mefloquine 
treatment.  
 
MATERIALS AND METHODS 
P. falciparum genomic DNA 
 Genomic DNA from two clonal P. falciparum strains was obtained from the 
Malaria Research and Reference Reagent Resource Center (MR4): 3D7 (MRA-102G) 
contains 1 pfmdr1 copy and Dd2 (MRA-150G) contains 4 pfmdr1 copies. Paired 
enrollment (pre-treatment) and recurrent parasitemias from five randomly selected 
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participants were obtained from a clinical trial conducted in the Chumkiri District, 
Kampot Province, in southern Cambodia between August 2006 and February 2008. The 
details of the study have been published elsewhere (130). In brief, subjects with 
uncomplicated mono-infection by P. falciparum with parasitemias between 1,000 and 
100,000 parasites/mm3 were included in this study. Parasitemias were determined by 
counting parasites per 1,000 red blood cells in Giemsa-stained blood films and 
multiplying by standard estimates of red blood cell counts (4,000,000 RBC/mm3) (130). 
Subjects with mixed Plasmodium infection, an unwillingness to remain at the clinic for 
directly observed therapy or to return for follow-up visits, or any sign of severe malaria 
according to World Health Organization criteria were excluded from this study. One 
hundred fifty-one subjects received directly observed therapy with 12 mg/kg artesunate 
(over three days) and 25 mg/kg mefloquine (two doses, eight hours apart), up to a 
maximum dose of 600 mg artesunate/1,000 mg mefloquine (130). Subjects were followed 
for 42 days or until recurrent parasitemia was observed. Blood was collected for 
examination on days 0, 1, 2, 3, 7, 14, 21, 28, 35, and 42, and at any time when the subject 
reported to the clinic with fever or other malaria-related symptoms. 
 
Development of TaqMan® Real-time PCR Limiting Dilution Assay 
Limiting dilution was used to obtain single copies of the P. falciparum genome 
(165, 166). Because all isolates that have been studied thus far show that any additional 
copies of pfmdr1 occur in tandem along chromosome 5 (117), we chose the single-copy 
RNA helicase-1 gene as the reference gene because it is also located on chromosome 5 
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but is outside of the size polymorphism responsible for the pfmdr1 gene amplification 
(PlasmoDB) (115). 
The pfmdr1 (PlasmoDB: PFE1150w) and RNA helicase-1 (PlasmoDB: 
PFE1390w) primers and fluorescent probes were designed using ABI’s Primer Express 
software and are as follows (5’ to 3’): (1) pfmdr1 forward primer: 
TGCCCACAGAATTGCATCTATAA, (2) pfmdr1 reverse primer: 
GACTGTACAAAGGTTCCATTTCGA, (3) pfmdr1 probe: FAM-
ACGATCAGACAAAATT-MGB, (4) RNA helicase-1 forward primer: 
TGATATCCCTGCACCAATAAAAAA, (5) RNA helicase-1 reverse primer: 
CCACTACCGGTAAACGCTATACCT, and (6) RNA helicase-1 probe: VIC-
AAGAAGCCAACACAAATTCAAATGCAAGGA-TAMRA. Each duplex real-time 
PCR reaction contained the following: 1µL of gDNA, ABI’s TaqMan® Gene Expression 
MasterMix (2X)6, 300nM each pfmdr1 primer, 200nM pfmdr1 probe, 900nM each RNA 
helicase-1 primer, 250nM RNA helicase-1 probe, and nuclease-free water to reach a total 
reaction volume of 20µL. We elected to use the TaqMan® Gene Expression MasterMix 
because it has been optimized for the amplification of small quantities of DNA7. The 
real-time PCR reactions were carried out using the 384-well block on an Applied 
Biosystems 7900HT Fast Real-Time PCR System1 under the following conditions: 50˚C 
for 2 minutes, 95˚C for 10 min., and 45 cycles of 95˚C for 15 seconds and 60˚C for 1 
min. Nuclease-free water and human gDNA extracted from whole blood were used as 
negative controls. P. falciparum 3D7 and Dd2 gDNA from MR4 at the following 
concentrations were used as positive controls: 10ng/µL and 1ng/µL. Although we 
                                                
6 Applied Biosystems, Inc.: Carlsbad, CA 
7 Personal communication with Chris Miller, Field Application Specialist, Applied Biosystems, Inc. 
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conducted the same calculations while correcting for differences in primer/probe 
efficiencies using a previously described method (31), we found that the slight alterations 
did not significantly affect the results. Therefore, the results presented were calculated 
using the ideal PCR cycle efficiency of 2, which states that the DNA template doubles at 
each PCR cycle. 
Serial dilutions of sample DNA were made and subjected to real-time PCR for 
RNA helicase-1. Dilutions were chosen in which amplification was observed in ~67% of 
the total number of replicate PCR wells. Assuming the Poisson distribution, 
approximately one-third of the replicates at the selected dilution would not contain any 
chromosome 5 DNA, one-third would contain one copy of chromosome 5, ~18% would 
contain two copies, and the rest would contain three or more copies of chromosome 5. 
Ct values (cycle at which probe fluorescence from DNA amplification crosses a 
threshold value) were determined for pfmdr1 and RNA helicase-1 in each individual 
replicate well. Pfmdr1 copy number was calculated using the Pfaffl ΔΔCt method (167). 
The wells in which the RNA helicase-1 Ct value was highest (i.e. the DNA product 
accumulates and exceeds a threshold value at a later PCR cycle, which suggests that there 
was less DNA in the well at the initiation of the PCR run) were categorized as wells 
containing one chromosome 5 at the outset. A decrease in RNA helicase-1 Ct value of 1.0 
indicated that there was twice as much initial DNA. These wells were categorized as 
having two initial copies of chromosome 5. For these wells, a three-fold difference in 
pfmdr1 copy number relative to the two copies of RNA helicase-1 was categorized as one 
variant with two pfmdr1 copies and one variant with one pfmdr1 copy. Figure 3.1 shows 
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the distribution of wells with RNA helicase-1 amplification (Ct) that were used in the 
limiting dilution assay analysis for Patient A. 
Wells with Ct values below 37 were excluded from the analysis since they were 
likely to contain three or more copies of chromosome 5. 
 
Mock Clinical Samples 
Live cultured P. falciparum parasites from the following MR4 strains were used: 
3D7 and Dd2. Parasites were combined with fresh type O+ human whole blood and 
spotted on sterile Whatman filter paper to mimic clinical samples with parasitemias of 
135 parasites/µL, 45 parasites/µL, and 15 parasites/µL. The blood spots were dried for 24 
hours at room temperature and then placed in plastic bags with a desiccant. QIAmp DNA 
Blood Mini Kits were used to extract gDNA from the entire 50µL blood spot. Extracted 
DNA was used to evaluate the assay sensitivity in the presence of human DNA under the 
real-time PCR conditions noted above. 
 
Use of Limiting Dilution Assay to assess pfmdr1 copy number in clinical samples 
 QIAmp DNA Blood Mini Kits8 were used to extract genomic DNA from dried 
blood spots of patients in Chumkiri, Cambodia (164), where malaria multidrug resistance 
is currently an issue. Five random patients with recurrent parasitemia following 
antimalarial treatment were selected for analysis. Blood spots from these patients were 
prepared from blood collected at two times during the study: (1) enrollment (i.e. before 
antimalarial treatment) and (2) at parasitemia recurrence following treatment. Real-time 
                                                
8 Qiagen, Inc.: Valencia, CA 
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PCR of preliminary dilution tests was performed to determine the appropriate dilution to 
achieve approximately one amplifiable chromosome 5 per well. Once the dilution factor 
was identified, real-time PCR was performed on multiple replicates of each sample at the 
selected gDNA dilution in a 384-well PCR plate, as described above. The ΔΔCt method 
(167) was used to evaluate pfmdr1 gene copy number relative to the single-copy RNA 
helicase-1 gene. Below is the formula for determining gene copy number from Ct values: 
Copy Number =   2CtRNA helicase-1 
     2Ctpfmdr1 
 
RESULTS 
Validation of RNA helicase-1 as the control gene for the limiting dilution assay 
 The objective of these experiments was to evaluate RNA helicase-1 as the control 
gene for our assay. Traditionally, P. falciparum lactate dehydrogenase or β-tubulin genes 
have been used for copy number analysis. Because the objective of this assay is to 
serially dilute the gDNA to obtain one amplifiable chromosome per well, we used RNA 
helicase-1 because it is located on the same chromosome as pfmdr1. Duplex PCR 
reactions were used so that each well was evaluated for amplification of the gene of 
interest (pfmdr1) and the reference gene (RNA helicase-1). Our results show that this 
assay can reproducibly detect difference in pfmdr1 copy number. At each serial dilution 
tested, we detected approximately four pfmdr1 copies in Dd2 parasites and one pfmdr1 
copy in 3D7 parasites (data not shown). These results validate the use of single-copy 
RNA helicase-1 as the reference gene of copy number analysis. 
 In order to determine the sensitivity of this new assay for DNA extracted from 
clinical samples, we determined pfmdr1 copy number from mock blood spots at known 
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parasitemia levels. Dried blood spots made from cultured 3D7 and Dd2 parasites mixed 
with whole human blood were used to mimic the clinical samples. Parasite strains in 
blood spots were as follows: 3D7 only, Dd2 only, and 3D7 + Dd2 (50:50, 3D7:Dd2). 
These were used to assess the ability of the assay to detect copy number changes in the 
presence of human DNA. Differences in pfmdr1 copies were reproducibly detected at 
blood spots from the lowest parasitemia tested (15 parasites/µL) (Figure 3.2). 
 
Comparison of pfmdr1 copy number profiles of initial and recurrent infections 
 The objective of these experiments was to evaluate pfmdr1 copy number in 
parasite subpopulations within an individual patient. Our limiting dilution assay was 
applied to genomic DNA extracted from dried blood spots from western Cambodia. 
Table 3.1 compares the median pfmdr1 copy numbers for each patient at enrollment and 
recurrence determined by our limiting dilution real-time PCR assay with the previously 
published results for these patients (130). Figure 3.3 depicts the percentage of wells with 
different pfmdr1 copy numbers for each patient before (gray bars) and after (black bars) 
AM treatment. For patients shown in Figure 3.3A and 3.3B, the recurrent samples were 
composed of parasites with higher numbers of pfmdr1 copies compared with their 
enrollment sample. Patients shown in Figure 3.3C and 3.3D had similar pfmdr1 copy 
numbers at enrollment and recurrence. Genotyping of the parasite genes msp1, msp2, and 
glurp (130) revealed that the recurrent parasitemias from these four patients (A-D) were 
recrudescences, or treatment failures. The patient shown in Figure 3.3E had the opposite 
result, with higher pfmdr1 copy numbers at enrollment compared with recurrence. 
Genotyping of this patient showed that recurrent parasitemia was the result of a 
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reinfection (130). The pfmdr1 copy number trends for these patients are consistent with 
the previous report of the average pfmdr1 copy number trend for this patient at 
enrollment and recurrence (130). 
 
DISCUSSION 
 Clinical failures of mefloquine monotherapy and of AM combination therapy 
have been linked to elevated copy number of the P. falciparum multidrug resistance 
(pfmdr1) gene in multiple studies. However, not everyone with high copy numbers fail 
and not all failures are associated with high copy numbers (27, 31-33, 114, 130, 164). 
Conventional copy number assays provide an average number of gene copies for the 
entire parasite population within an individual patient. It is possible that patients might 
have a low average copy number but recrudesce because of a small subpopulation of high 
copy number parasites. Thus, we attempted to develop a method of identifying minority 
variants with high pfmdr1 copy numbers. 
 We first developed a new pfmdr1 copy number assay. Since serial dilutions of 
DNA, not parasites, were being made, we needed a reference gene that was located on the 
same chromosome as pfmdr1. RNA helicase-1 is also located on chromosome 5 but is 
outside of the size polymorphism responsible for pfmdr1 copy number increases 
(PlasmoDB). Copy numbers were assessed using the Pfaffl ΔΔCt method (167), which 
compares crossover threshold (Ct) values of the target gene (pfmdr1) and the reference 
gene (RNA helicase-1). In mock clinical samples, this assay was able to reproducibly 
detect the correct relationship between pfmdr1 copy number and single-copy RNA 
helicase-1 (Figure 3.2). For patient samples (Table 3.1), our median pfmdr1 copy number 
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determinations were very similar to those published previously using conventional 
methods (130). 
 Blood spots from five patients were used to assess the efficacy of this assay on 
clinical samples from a region where drug resistant malaria is present. Four of the 
patients (A-D) were classified as recrudescent (treatment failures) based on msp1, msp2, 
and glurp genotyping (130). Of these four paired isolates, two showed higher pfmdr1 
copy numbers from recurrent gDNA compared with enrollment (day 0) gDNA (Figure 
3.3A-3.3B) and two showed similar copy numbers at both enrollment and recurrence 
(Figure 3.3C-3.3D). These data suggest that elevated pfmdr1 copy number is sometimes 
selected by drug treatment but is sometimes not. Thus, treatment failure could be due to 
other parasite mutations or to host factors (178-179). One paired isolate (Patient E) was 
from a patient who was cured and reinfected (130). The pfmdr1 copy numbers were 
lower at follow-up (day 21). Particularly interesting for patient E was the presence of 
recurrent parasites with single copies of pfmdr1 that were not found at enrollment. This 
indicates that drug-sensitive strains were introduced after this patient completed treatment 
(i.e. reinfection). 
 Our limiting dilution copy number assay provides new information about the 
percentage of parasites with multiple pfmdr1 gene copies that are present in an individual 
patient and how that frequency changes after antimalarial treatment. Although this assay 
is labor intensive, clinical blood spots can be easily collected and stored in desiccant at 
4°C to be analyzed at a later date. Further analysis of clinical isolates from multidrug 
resistant malaria regions using this assay would be worthwhile to gain insight into the 
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minimum frequency of parasites with elevated pfmdr1 copy numbers required to cause 
recrudescence. 
  
  
 55 
 
Figure 3.1: Distribution of RNA helicase-1 Ct values used in pfmdr1 copy number analysis by the 
limiting dilution real-time PCR assay. These data show the distribution (percentage of total PCR-positive 
wells) of RNA helicase-1 Ct values for patient A at enrollment (gray bars) and recurrence (black bars). As 
described in the methods section, the RNA helicase-1 Ct value was used to determine the number of 
amplifiable copies of chromosome 5 that were present in a well. Assuming the Poisson distribution, the 
ideal distribution would show ~33% of wells with an RNA helicase-1 Ct value of 38 (one copy of 
chromosome 5) and ~18% of wells with an RNA helicase-1 Ct value of 37 (two copies of chromosome 5). 
For the enrollment sample depicted above, RNA helicase-1 Ct values of 38.6-39.0 contain one chromosome 
5 copy and Ct values of 37.3-37.7 contain two chromosome 5 copies. For the recurrence sample, Ct values 
of 37.5-37.9 contain one chromosome 5 copy and Ct values of 36.7-36.9 contain two chromosome 5 copies. 
The differences in Ct values for the wells containing a single copy of chromosome 5 between the two 
samples is likely due to normal inter-plate run differences in real-time PCR. 
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Figure 3.2: Pfmdr1 copy number relative to single-copy RNA helicase-1 assessed from mock blood 
spots. Cultured 3D7 and Dd2 parasites were added to whole human blood at serial 1:3 dilutions and spotted 
onto filter paper to mimic clinical samples. Equal numbers of 3D7 and Dd2 parasites were added to whole 
blood for the 3D7+Dd2 blood spots. Genomic DNA was isolated from each blood spot and used in the real-
time PCR assay to confirm the validity of the assay on parasite DNA in the presence of human DNA. As 
anticipated, the fold difference in pfmdr1 relative to single-copy RNA helicase-1 for the combined 
(3D7+Dd2) blood spots reproducibly amplified halfway between those for each strain alone. 
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Table 3.1: Comparison of pfmdr1 copy numbers (CN) for clinical samples at enrollment and at 
recurrent parasitemias between our limiting dilution assay and the published results for these 
patients (130) 
 
Patient 
ID 
pfmdr1 CN at enrollmenta pfmdr1 CN at recurrenceb day of recurrent 
parasitemia published CN limiting dilution CNd published CN 
limiting 
dilution CNd 
A 1.3 1 (69) 2.3 2 (62) 21 
B 2.9 2.5 (69) 4.3 4 (21) 35 
C 1.9 1 (53) 2.1 2 (17) 21 
D 1.1 2 (36) 1.1 2 (18) 28 
Ec 3.7 5.5 (56) 3.1 4 (11) 21 
 
aEnrollment refers to the sample that was collected at the beginning of the study. 
bRecurrence refers to the sample that was collected at the final follow-up time point for patients that were 
parasitemic. 
cThe study from which these samples came was published in the following article: Rogers WO, et al. 
Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria 
in southern Cambodia. Malaria Journal. 2009; 8:10. 
dLimiting dilution copy numbers were not normally distributed. Therefore, the median value is listed here. 
The number of wells used to calculate each median is given in parenthesis. 
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Figure 3.3: Distribution of parasite pfmdr1 
copy number within a patient before and after 
treatment with artesunate-mefloquine 
combination therapy. Serial dilutions of 
genomic DNA extracted from patient blood spots 
were analyzed using the described real-time PCR 
assay. The dilution factor that gave rise to 
amplification for both genes in approximately 
67% of the wells was used for copy number 
analysis by real-time PCR. Pfmdr1 copy number 
assessment was done on replicate wells from the 
second PCR assay. Gray bars represent pfmdr1 
copy numbers of parasites within the patient at 
day 0 (enrollment). Black bars represent pfmdr1 
copy numbers within the same patient at 
recurrence of parasitemia. 
  
  
 
 
 
CHAPTER IV 
Quinine Localizes to a Non-Acidic Compartment within the Food Vacuole of the Malaria 
Parasite Plasmodium falciparum 
 
INTRODUCTION 
Quinine (QN) was isolated from the bark of the Peruvian cinchona tree in the 
mid-1800s (19) and quickly became the treatment of choice for intermittent fever 
worldwide (24). Although efficacious, QN use as an antimalarial requires a relatively 
long treatment regimen and has substantial side effects. As a result, artemisinin-based 
combination therapies (ACT) have now been implemented as first-line treatment 
regimens due to drug efficacy and better patient tolerance. Because ACTs are 
prohibitively expensive or unavailable in regions where resources are limited, QN 
remains an important therapy to treat uncomplicated and severe malaria infections (4, 46, 
168). Despite the longevity of its use as an antimalarial, the mechanism of action of 
quinine has not yet been fully resolved. 
Early investigations into the antimalarial activity of QN demonstrated the ability 
to inhibit chloroquine-induced clumping of hemozoin in the parasite food vacuole (169). 
Subsequent evidence found that, like chloroquine, QN interferes with heme 
polymerization (170, 171), indicating that quinine acts in the food vacuole. In recent 
years, parasite resistance to QN has been reported in Africa and Southeast Asia, 
prompting investigations into resistance mechanisms with a focus on the food vacuole 
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(26, 29, 32, 168, 172, 173). Decreased QN sensitivity has been strongly linked to a 
protein on the food vacuolar membrane, encoded by the Plasmodium falciparum 
multidrug resistance (pfmdr1) gene (26, 32, 39, 110, 173, 174). Whereas some studies 
have found that pfmdr1 mutations exert a significant effect on in vitro quinine sensitivity 
(26, 29, 110), other studies have found no association between pfmdr1 mutations and 
quinine sensitivity (27, 28, 175). Elevated pfmdr1 gene copy number, however, has been 
linked to reduced parasite susceptibility to quinine in both in vitro and clinical studies 
(27, 28, 30, 32, 174). Thus, pfmdr1 has an effect on QN activity. 
Quinine is an aromatic alkaloid compound that naturally fluoresces under 
ultraviolet (UV) light. Because of its relatively constant fluorescence quantum yield, 
quinine is commonly used in photochemistry as a fluorescence standard (176). In this 
study, we exploited the fluorescent properties of quinine to evaluate subcellular 
localization of the drug by fluorescence microscopy in parasites containing different 
pfmdr1 copy numbers to determine if copy number of the gene affects drug localization. 
 
MATERIALS AND METHODS 
Parasite cultivation 
We used P. falciparum cultures of two clonal parasite strains (3D7 and Dd2) with 
different pfmdr1 copy numbers and quinine (QN) sensitivity. The 3D7 strain has one 
pfmdr1 copy and is sensitive to QN. The Dd2 strain has four pfmdr1 copies and is 
resistant to QN. Cultures were maintained at 37°C under the Trager-Jenson method for 
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malaria parasite culturing (134). Type O+ serum at 10% and red blood cells9 at 2% 
hematocrit were used in culturing and experimental conditions. 
 
Imaging of parasites using fluorescence microscopy 
 Live asynchronous cultures were incubated with 1µM of QN and imaged over an 
11-hour period using fluorescence microscopy. Time-lapse imaging of multiple parasites 
was carried out with a Prior Scientific10 motorized x-y stage. An incubator box 
maintained the microscope work area including the objective at 37°C. LysoTracker DND 
Red11 (50nM) was used to stain the food vacuole and DRAQ512 (1µM) was used to stain 
DNA. Fluorescence images were acquired using an Olympus FV1000 inverted IX81 
microscope with a 63x 1.42 NA oil immersion objective at the UNC-Chapel Hill Michael 
Hooker Microscopy Core Facility. Serial sections with step sizes of 0.20 or 0.25µm were 
gathered using sequential scanning at 405nm (quinine), 559nm (LysoTracker Red) & 
635nm (DRAQ5) excitation, and 435/50nm, 595/50nm & 705/100nm emission 
respectively. Confocal pinhole was set to maximum (800µm, ~8 Airy units). Laser 
transmitted light differential interference contrast (DIC) images were collected at an 
optimum z-level separately. Image stacks were deconvolved using the iterative blind 
deconvolution method with Volocity Image Analysis software, version 5.5213. 
Occasionally, Tetraspec 0.1µm beads (Molecular Probes, OR) were added to the sample 
and used for deconvolution with measured point spread functions. 3-D opacity volume 
rendering and 3-D colocalization analysis was carried out with Volocity. 
                                                
9 Research Blood Components, LLC: Boston, MA 
10 Prior Scientific: Rockland, MA 
11 Invitrogen: Carlsbad, CA 
12 Biostatus Limited: Leicestershire, United Kingdom 
13 Perkin Elmer: Waltham, MA 
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RESULTS 
Quinine localizes to the parasite food vacuole 
 Two-dimensional (2-D) fluorescence and DIC images of both 3D7 (one pfmdr1 
copy) and Dd2 (four pfmdr1 copies) parasites showed that quinine (QN) colocalizes with 
hemozoin, which suggests localization in the parasite food vacuole (Figure 4.1). The 
colocalization was highly repeatable and seen in four fields in at least ten experiments. 
Parasites were also imaged at earlier time points following the addition of QN (beginning 
at one hour of exposure through 11 hours). QN fluorescence was found in the food 
vacuole as early as one hour of exposure and remained there for the duration of the 
experiment (Figure 4.2). This effect appears to be independent of pfmdr1 copy number as 
experiments in both strains rendered similar results. The same pattern was seen regardless 
of whether the infected red cells were maintained on the heated microscope stage or in a 
candle jar, indicating that photobleaching was not a factor. 
To further characterize subcellular localization of QN, we determined whether it 
colocalized with either LysoTracker Red, which localizes to acidic compartments, or 
DRAQ5, which localizes to the nucleus, using three-dimensional (3-D) reconstruction of 
z-stack fluorescence images. As expected, no colocalization with DRAQ5 was seen. 
However, QN was found to localize in a separate but adjacent compartment from that in 
which LysoTracker Red was localized (Figure 4.3). This 3-D imaging method does not 
allow for hemozoin to be visualized. The pattern of colocalization was the same for 3D7 
and Dd2 parasites, despite their differences in pfmdr1 copy number. These observations 
suggest that QN localizes to a distinct, non-acidic compartment within the parasite food 
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vacuole, possibly overlapping with hemozoin in parasites with both low and high pfmdr1 
copy number. 
 
DISCUSSION 
 Although quinine was the first therapeutic compound used to treat malaria 
infection (19), its mechanism of action has never been fully resolved (169-171). Some 
evidence suggests that parasite resistance to quinine is associated with mutations and/or 
elevated copy number of the pfmdr1 gene, which encodes for a transporter protein found 
in the membrane of the parasite food vacuole (26, 27, 28, 29, 30, 32, 110, 172, 174). 
Here, we exploit the natural fluorescent properties of quinine to obtain insight into the 
mechanism of action of the drug. Although knowledge of quinine’s fluorescent properties 
has been around since the late-1800s (177), this is the first study to employ the quinine’s 
fluorescence for imaging in the malaria parasite. 
We employed fluorescence microscopy to image quinine subcellular localization 
in two P. falciparum strains that contained different pfmdr1 copy numbers. Quinine 
consistently overlapped with the hemozoin crystals in both strains when evaluated by 
two-dimensional microscopy (Figure 4.1). However, upon 3-D reconstruction of serial z-
stack images, we found the quinine resides in a distinct compartment, which is 
contiguous to, but separate from, the compartment stained by LysoTracker Red. The lack 
of colocalization with the acidotropic dye suggests that quinine resides in a non-acidic 
compartment within the food vacuole, possibly the same one occupied by hemozoin. This 
would be consistent with previous reports that it interacts with hemozoin crystals directly 
or with enzymes involved in the hemozoin crystallization process, as previously reported 
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(170, 171). In summary, our findings suggest that QN is localized in the food vacuole but 
outside of the acidic compartment. 
This study underscores the importance of utilizing the 3-D reconstruction 
software in imaging studies, since the localization of quinine into this novel compartment 
would not have been detected otherwise. Although there was no apparent difference in 
localization in strains containing different pfmdr1 copy numbers, we cannot rule out the 
possibility that the pfmdr1 gene has a role. Single nucleotide polymorphisms in pfmdr1 
have also been associated with decreased sensitivity to quinine (26, 29, 110). Because the 
protein encoded by pfmdr1 is a membrane transporter that pumps solutes into the food 
vacuole, it is possible that mutations within the pfmdr1 gene could affect the transporter 
function of the protein. 
In summary, this study is novel because it is the first to exploit QN fluorescence 
to study the intracellular distribution of the drug. Here, we demonstrate that QN enters a 
distinct, non-acidic compartment inside the parasite food vacuole. These results are 
important because they provide visual support for the hypothesis that QN interferes with 
hemozoin production, which could guide future studies to investigate a possible 
interaction between QN and enzymes involved in the hemozoin formation process. 
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Figure 4.1: Quinine localizes with hemozoin in the parasite food vacuole. Trophozoites of P. 
falciparum strains 3D7 (one pfmdr1 copy) and Dd2 (four copies) were incubated with QN to determine its 
subcellular localization. The scale bar represents 5µm. White arrows point to hemozoin crystals in the food 
vacuole. Quinine overlapped with hemozoin in both strains and thus localized to the food vacuole.  
	  66	   	  	  Figure	  4.2:	  Quinine	   localization	  over	   time	   in	  Plasmodium	  falciparum.	  Trophozoites	  of	  P.	  falciparum	  strains	  were	  incubated	  with	  quinine	  (blue)	  to	  determine	  subcellular	  localization	  of	  the	  drug	  over	  an	  11-­‐hour	  period.	  White	  arrows	  point	  to	  hemozoin	  crystals	  in	  the	  food	  vacuole.	  Quinine	  overlapped	  with	  hemozoin	  crystals	  at	  all	  time	  points	  assessed.	  The	  scale	  bar	  represents	  5μm.	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Figure 4.3: 3-D reconstruction of Plasmodium falciparum parasites. Z-stack images of each parasite 
shown in Figure 4.2 were used for 3-D volume rendering and colocalization analysis. No quinine 
colocalization with LysoTracker Red was observed in either the 3D7 (left) or the Dd2 (right) strain. 
Because LysoTracker Red is highly specific for acidic organelles, quinine appears to be in a separate and 
non-acidic compartment of the food vacuole. 
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CHAPTER V 
Dissertation Summary and Future Directions 
 
SUMMARY 
 The focus of this dissertation was to evaluate the molecular aspects and clinical 
relevance of the pfmdr1 gene in the resistance to antimalarial drugs. This is important 
because numerous in vitro and clinical studies have linked elevated pfmdr1 copy number 
to decreased sensitivity several different antimalarial compounds. Future studies on ways 
to circumvent pfmdr1-mediated resistance would benefit from a better understanding the 
interplay between pfmdr1 and drug treatment. 
First, we explored the effect of MFQ treatment on pfmdr1 gene expression in 
parasite strains containing different pfmdr1 copy numbers: 3D7 (1 pfmdr1 copy), FCB (2 
copies), and Dd2 (4 copies). Parasites with multiple pfmdr1 gene copies exhibited higher 
relative transcript levels than single-copy parasites, and MFQ induced pfmdr1 expression 
above untreated levels in all three strains evaluated. Concomitant morphology analyses of 
the sampled cultures revealed an interesting phenomenon. Our data demonstrated that the 
MFQ treatment of synchronized ring-stage parasites induced a delay in parasite 
maturation through the intraerythrocytic cell cycle. This delay was specific to MFQ 
treatment and was observed in both MFQ-sensitive (3D7, FCB) and MFQ-resistant (Dd2) 
P. falciparum strains. Together, our expression and morphology data showed that peak 
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pfmdr1 expression levels were observed when the cultures had the highest percentage of 
ring-stage parasites, revealing stage-specific pfmdr1 expression. The benefit of 
prolonging the ring stage for multi-copy parasites could be to allow time for the increased 
expression of ring stage genes like pfmdr1. More pfmdr1-encoded transporters may 
displace sufficient amounts of MFQ to allow the parasite to survive treatment in strains 
with multiple pfmdr1 copies. 
Next, we developed a limiting dilution assay that evaluated pfmdr1 copy number 
in subpopulations of parasites within patients that failed artesunate-mefloquine (AM) 
treatment. The purpose of this study was to evaluate the distribution of subpopulations 
with elevated pfmdr1 copy numbers before AM treatment and in recurrent infections 
following AM failure. The output of conventional copy number assays is an average copy 
number for the entire parasite population. Our assay is the first to assess copy number on 
subpopulations. We found that parasites with several pfmdr1 copies, even if present in 
smaller relative quantities, have a greater influence over the patient’s response to 
treatment than the more abundant single-copy parasites. Moreover, our limiting dilution 
assay provides new information about the frequency of parasites with elevated pfmdr1 
gene copies that are present in an individual patient and how that frequency changes after 
antimalarial treatment. The ability to detect minority variants with increases in pfmdr1 
copy number might be able to better predict in vivo antimalarial treatment failure. This 
assay can be utilized on samples from multidrug resistant regions to determine the 
minimum frequency of parasites containing multiple pfmdr1 copies within a patient that 
is required to cause clinical treatment failure. 
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Finally, we imaged malaria parasites with fluorescence microscopy to determine 
the subcellular localization of the oldest antimalarial compound quinine (QN). The goal 
of this study was to utilize the naturally fluorescent properties of QN to determine its 
subcellular localization in malaria parasites with different pfmdr1 copy numbers. 
Decreased QN sensitivity has been linked in clinical studies and in vitro to elevated 
pfmdr1 copy number. Our results showed that QN consistently overlapped with hemozoin 
crystals in the parasite food vacuole. We observed apparent colocalization of QN and 
LysoTracker Red in the two-dimensional (2-D) images of multi-copy Dd2 parasites but 
not single-copy 3D7 parasites. This suggested that the extra pfmdr1 gene copies in Dd2 
result in an increased pumping of QN into the food vacuole by the pfmdr1-encoded 
transporter. However, upon three-dimensional (3-D) reconstruction of serial z-stack 
images, we found the QN exhibits no colocalization with LysoTracker Red in either 3D7 
or Dd2 parasites and thus resides in a distinct, non-acidic compartment within the food 
vacuole. These results demonstrate the importance of utilizing 3-D rendering software 
and illustrate the possibility of drawing inaccurate or incomplete conclusions when 
relying solely on 2-D imaging. These findings are novel because they are the first visual 
evidence of QN subcellular localization within the malaria parasite and serve as the 
foundation for future studies of QN activity within the parasite food vacuole. 
Taken together, the findings of this dissertation accomplished our objective to 
more fully evaluate the role of the pfmdr1 gene in drug resistance in the malaria parasite. 
First, we identified that pfmdr1 is primarily transcribed during the ring stage of the 
parasite intraerythrocytic cycle. Even though MFQ induced a maturation delay at the ring 
stage in all strains, this ring stage-dependent pfmdr1 expression would explain how 
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parasites with multiple pfmdr1 gene copies evade destruction by producing more pfmdr1-
encoded transporters than single-copy parasites. Second, our limiting dilution assay 
revealed that some patients that fail antimalarial treatment are infected with parasite 
subpopulations with multiple pfmdr1 copy numbers at a higher frequency than those that 
do not fail. We found that there is a greater percentage of subpopulations containing more 
than five pfmdr1 copies than previously believed, based on conventional copy number 
assays that measure the average gene copies for the entire population. And third, we show 
the first visual data for subcellular localization of QN within the malaria parasite. This is 
important because it reveals a novel putative site of QN activity within the food vacuole. 
Exploiting the natural fluorescence in QN by fluorescence microscopy is the foundation 
for future studies that address differences in subcellular localization between QN-
sensitive and QN-resistant parasites. Because of the vast amount of data that links pfmdr1 
to antimalarial resistance, understanding the expression of this gene and the degree of its 
influence over parasite response to drug exposure can aid in the development of therapies 
that circumvent such broad antimalarial resistance.  
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